home
Assets:
cash
current-assets
inventory
receivables
investments
invested
ppe
nta
assets
net-debt
working-capital
liabilities
long-term-debt
accounts-payable
non-current-liabilities
Income sheet
sales
operations-income
gross-profit |
expenses
marketing
r-and-d
income-before-tax
tax
income
net-income
interest-income
ebit
leases
interest
earnings
Key Financials FIXX
| Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts. |
| symbol | last | change | %chng | name | mcap | sector | wiki |
|---|
| FIXX | | | | Homology Medicines Inc | 0.003B | Healthcare | |
| symbol | prev.close | range | chart | target | percent | period | months | due | rating |
|---|
| D | FIXX | 0.00 | 0,-1.115,-5.000,0.231,-1.115 | 0.61,0.58,0.62,0.68,0.70,0.73,0.85,0.91,0.89,0.91,7.07,0.93 | 0.47-0.63 | | 267,105,267 | 5.4 | Jan 5-Sep 28 | 44.13% |
0 FIXX US
MyShare